Alkermes stock has recently seen its fair value estimate increased from $42.53 to $44.00 per share, driven by a wave of new developments and shifting analyst sentiment. In addition, the discount rate ...

ORX750: Demonstrated potential best-in-class profile for treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic ...

Centessa Pharmaceuticals executives will be breathing a sigh of relief as its stock price recovered after a drop caused by ...

Centessa Pharmaceuticals Plc ( ($CNTA) ) has released its Q3 earnings. Here is a breakdown of the information Centessa Pharmaceuticals Plc ...

Q3 2025 Earnings Call Transcript November 4, 2025 Harmony Biosciences Holdings, Inc. misses on earnings expectations.

Generated LUMRYZ™ net product revenue of $77.5 million, a 55% increase compared to third quarter 2024 – – Approximately 3,400 patients on LUMRYZ as of September 30, 2025, a 48% increase compared to ...

Harmony Biosciences Holdings Inc (HRMY) reports a 29% revenue increase and raises full-year guidance amid robust patient ...

The U.S. FDA’s complete response letter (CRL) for Biohaven Ltd.’s lead asset, troriluzole, to treat spinocerebellar ataxia has prompted a wave of downstream changes at the company. There will be a ...

Harmony Biosciences posts record Q3 2025 results with 29% revenue growth, boosts outlook, and highlights pipeline progress.

The pharmaceutical company posted adjusted earnings of $1.08 per share for Q3 2025, handily beating the analyst consensus of $0.74. Revenue surged to $239.5 million, representing 29% YoY growth and ...

Khaberni - A recent study has revealed a rare condition known as Idiopathic Hypersomnia (IH), where sufferers experience ...

Around 2,000 people visit A&E every year due to injuries caused by fireworks. Although fireworks are an essential part of Bonfire Night celebrations for many revelers, these colorful pyrotechnics can ...